Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

前日（2月7日）， 全球骨科手术机器人龙头企业Globus Medical（NYSE: GMED）宣布以每股5.85美元的价格收购慢性疼痛治疗公司Nevro（NYSE: NVRO）全部股份，总股权价值达2.5亿美元（约合18.2亿元人民币） 。这一价格较Nevro过去90天的平均股价溢价27%，较30天平均股价溢价38%，交易预计于2025年第二季度末完成。

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus will pay $5.85 per share in an all-cash purchase, a 27% premium to Nevro’s 90-day volume-weighted average price. Globus CEO Dan Scavilla said in a statement that the purchase “furthers ...

President and CEO of Globus Medical. “In addition, our scale and operational discipline will allow us to optimize Nevro’s financial performance to drive enhanced profitability and create long ...

CEO Dan Scavilla said the deal will allow the company to expand into new markets for future growth. "We believe our size and operational capabilities will accelerate market penetration of Nevro ...

President and CEO of Globus Medical. "In addition, our scale and operational discipline will allow us to optimize Nevro's financial performance to drive enhanced profitability and create long-term ...

AUDUBON, Pa. - Globus Medical , Inc. (NYSE: NYSE:GMED), a prominent musculoskeletal solutions company with a market capitalization of $11.81 billion and an "GREAT" financial health rating according to ...